Eli Lilly forecasts 2025 profit largely above estimates

Eli Lilly’s Annual Profit View in Line After Recent Misses
Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory problems with its new blockbuster obesity and diabetes drugs that weighed on sales in recent quarters.
Eli Lilly And Co. Q4 Profit Increases, Beats Estimates
Eli Lilly And Co. (LLY) reported earnings for its fourth quarter that increased from last year and beat the Street estimates. The
Eli Lilly Adjusted Profit Tops Estimates as Weight-Loss Drug Sales Fall Short
Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.
Eli Lilly’s earnings, shares lifted by obesity drug sales
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for its weight loss medicines in January.
Diabetes and Obesity Drugs Fuel Eli Lilly Profit in the Final Quarter of 2024
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast
Eli Lilly forecasts 2025 profit largely above estimates on launch of weight-loss drug in new markets
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular diabetes and weight-loss treatments in new markets.
Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars
CNBC's Angelica Peebles joins 'Squawk Box' to report on the company's quarterly earnings results.
FierceBiotech13h
UPDATED: Eli Lilly lops Alzheimer's and obesity assets from pipeline in Q4 update
In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs ...
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...
Eli Lilly reports mixed earnings, increases 2025 guidance
Lilly upgraded its 2025 guidance to between $58 billion to $61 billion, slightly higher than Wall Street expectations by $1 ...
FierceBiotech8h
Eli Lilly's next R&D focus: Testing incretin meds in neuro, immunology fields
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
MM&M1d
Inside Eli Lilly’s bold breast cancer awareness ad debut at the Grammys
Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...
What Analysts Think of Eli Lilly Stock Ahead of Earnings
Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.
Eli Lilly and Company: Lilly reports full Q4 2024 financial results and provides 2025 guidance
Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...
Eli Lilly Guides FY25 In Line With Estimates - Update
While reporting financial results for the fourth quarter on Thursday, drugmaker Eli Lilly and Co. (LLY) initiated its earnings, ...